Blog

Merck’s immunotherapy, chemo mix shows extended lung cancer gains – Reuters

Merck's immunotherapy, chemo mix shows extended lung cancer gains
Reuters
MADRID (Reuters) – Giving Merck & Co's immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial.

2017-09-07 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.